13F Holdings
中文EN

CAH CARDINAL HEALTH INC

Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 721371 · Fiscal year ends 06/30

Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY14.2%
TTM net income YoY9.8%
TTM EPS YoY12.1%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR73.2%

Margins

Gross margin3.8%
Operating margin1.0%
Net margin0.7%
FCF margin1.8%
EBITDA margin1.4%

Returns

ROE—
ROA3.1%
ROIC (approx.)135.8%
Asset turnover4.61x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio0.88x
Interest coverage7.51x

Cash quality & payout

Operating cash flow / net income3.02x
Accruals ratio-6.3%
Payout ratio28.6%
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$254.25B$222.58B$226.83B$204.98B$181.33B
Cost of revenue$244.47B$214.41B$219.41B$198.10B$174.84B
Gross profit$9.77B$8.17B$7.41B$6.87B$6.48B
SG&A expense$6.13B$5.38B$5.00B$4.80B$4.51B
Operating income$2.61B$2.27B$1.24B$752.00M-$607.00M
Interest expense$348.00M$215.00M$51.00M$84.00M$147.00M
Pretax income$2.17B$2.10B$1.20B$663.00M-$784.00M
Income tax$469.00M$532.00M$348.00M$332.00M$153.00M
Net income$1.71B$1.56B$852.00M$330.00M-$938.00M
EBITDA$3.57B$3.06B$1.95B$1.44B$85.00M
EPS (basic)7.276.483.481.27-3.37
EPS (diluted)7.236.453.451.26-3.37
Dividends declared per share2.042.022.001.981.96
Weighted avg. shares (diluted)237.00M242.00M247.00M262.00M279.00M
Balance sheet
Cash & equivalents$4.86B$3.87B$5.13B$4.08B$4.75B
Short-term investments——$200.00M——
Receivables$13.81B$13.24B$12.08B$11.11B$10.56B
Inventory$17.30B$16.83B$14.96B$16.12B$15.64B
Current assets$38.75B$36.37B$34.88B$33.74B$32.94B
PP&E, net$3.03B$2.86B$2.53B$2.46B$2.36B
Goodwill$11.44B$9.69B$4.72B$4.61B$5.86B
Intangibles$2.19B$2.49B$1.73B$1.47B$1.77B
Total assets$57.30B$53.12B$45.12B$43.35B$43.88B
Current liabilities$43.90B$38.90B$35.64B$33.74B$30.55B
Short-term debt$1.88B$550.00M$434.00M$792.00M$580.00M
Long-term debt$7.00B$7.98B$4.66B$3.91B$4.74B
Total debt$8.89B$8.53B$5.09B$4.70B$5.32B
Total liabilities$60.02B$55.76B$48.33B$46.31B$44.76B
Shareholders' equity-$2.88B-$2.78B-$3.21B-$2.96B-$709.00M
Net debt$4.03B$4.65B-$41.00M$625.00M$570.00M
Cash flow statement
Operating cash flow$5.17B$2.40B$3.76B$2.84B$3.17B
Capital expenditure$649.00M$547.00M$511.00M$481.00M$387.00M
Free cash flow$4.53B$1.85B$3.25B$2.36B$2.79B
Investing cash flow-$2.58B-$5.59B-$1.85B-$454.00M$567.00M
Financing cash flow-$1.60B$1.94B-$847.00M-$3.05B-$2.46B
Depreciation & amortization$956.00M$790.00M$710.00M$692.00M$692.00M
Stock-based compensation$367.00M$244.00M$121.00M$96.00M$81.00M
Dividends paid$491.00M$494.00M$499.00M$525.00M$559.00M
Share buybacks$1.36B$765.00M$750.00M$2.00B$1.00B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.